T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions in Patients with Relapsed Multiple Myeloma
Lekha Mikkilineni, James N. Kochenderfer(National Institutes of Health), Constance M. Yuan(National Cancer Institute), Elisabet E. Manasanch(National Institutes of Health), Danielle Vanasse(National Institutes of Health), Jennifer N. Brudno(National Institutes of Health), Micaela Ganadan(National Institutes of Health), Maryalice Stetler‐Stevenson(National Cancer Institute), Ronald E. Gress(National Institutes of Health), David F. Stroncek(Yale University), Norris Lam(National Institutes of Health), Jennifer Mann(National Institutes of Health), Nathan D. Trinklein(Children's Cancer Center), Rashmika Patel(National Institutes of Health), Hao‐Wei Wang(Fu Jen Catholic University), Jeremy J. Rose(National Institutes of Health), Irina Marić(Center for Cancer Research), Ben Buelow
Cited by 46
Related Papers
An integrated encyclopedia of DNA elements in the human genome
|Nature|2012|19.6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
An integrated encyclopedia of DNA elements in the human genome
|The Journal of the American Medical Association (JAMA) Network (American Medical Association)|2012|2.8k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k